Deep Value: cash covers about 99% of the stock price

This company holds roughly $7M in cash and investments — about 99% of its entire stock-market value, based on its latest quarterly filing. You're paying very little for the actual business. Sometimes that's a genuine bargain or a takeover target, sometimes it's cheap for a reason. Not a buy signal on its own — always ask why it's this cheap.

Imunon

IMNN

Biotechnology · Healthcare

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

Imunon, Inc. is a small clinical-stage biotechnology company focused on developing cancer treatments. Its main approach uses a technology called TheraPlas, which delivers DNA-based therapies directly into tumors to trigger an immune response against cancer cells. The company is primarily targeting ovarian cancer and other solid tumors, with its lead drug candidate, IMNN-001, in clinical trials.

Imunon does not yet generate meaningful revenue, as its drugs are still being tested in clinical trials and have not received regulatory approval. The company is based in the United States and funds its operations mainly through equity offerings and grants, which is typical for early-stage biotech firms. Its key competitive angle is its non-viral DNA delivery platform, which avoids some safety concerns linked to viral delivery methods. The biggest risk the company faces is the uncertainty of clinical trial outcomes — if its drug candidates fail to show sufficient safety or effectiveness, the company could struggle to survive without additional funding.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+71.1% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

15.0%ownership

Insiders own a meaningful stake in the company

Cash Runway

~0 months

$7M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Imunon has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-132.2%

Weak — -132.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

8/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

1.68

Elevated debt (1.68)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial